Literature DB >> 9279493

Maintenance of HIV risk reduction among injection opioid users: a 12 month posttreatment follow-up.

L M Camacho1, N G Bartholomew, G W Joe, D D Simpson.   

Abstract

Study objectives were to examine HIV risk behaviors 12 months following methadone maintenance (MM) treatment termination, and to assess the effects of treatment tenure, cocaine use, and gender on posttreatment HIV risk. Injection and sex risk behaviors were measured at treatment entry and 12 months after leaving treatment among 435 injection opioid users. Multi-way contingency tables for treatment tenure and HIV risk at treatment intake and at 12 month follow-up were analyzed using the GSK weighted least-squares estimation procedure. The effects of treatment tenure, gender, and cocaine use on risk behavior at follow-up, while controlling for intake risk and background variables were tested using a series of multiple logistic regression analyses. Results showed that injection and sex risk behaviors were significantly lower at 12 month follow-up than at treatment entry. Additionally, increased tenure was related to risk reductions, while cocaine use was related to increased risk-taking. Gender was generally unrelated to risk changes. These findings support broader use of MM in helping reduce HIV risks among injection drug users and highlight the need to explore ways to encourage treatment compliance in order to reduce risky practices.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9279493     DOI: 10.1016/s0376-8716(97)00056-2

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  12 in total

1.  Social contextual factors associated with entry into opiate agonist treatment among injection drug users.

Authors:  Jacqueline J Lloyd; Erin P Ricketts; Steffanie A Strathdee; Llewellyn J Cornelius; David Bishai; Steven Huettner; Jennifer R Havens; Carl Latkin
Journal:  Am J Drug Alcohol Abuse       Date:  2005       Impact factor: 3.829

2.  Risk factors in the relationship between gender and crack/cocaine.

Authors:  C W Lejuez; Marina A Bornovalova; Elizabeth K Reynolds; Stacey B Daughters; John J Curtin
Journal:  Exp Clin Psychopharmacol       Date:  2007-04       Impact factor: 3.157

3.  Hospital- versus community-based syringe exchange: a randomized controlled trial.

Authors:  Carmen L Masson; James L Sorensen; David C Perlman; Michael S Shopshire; Kevin L Delucchi; TeChieh Chen; Karl Sporer; Don Des Jarlais; Sharon M Hall
Journal:  AIDS Educ Prev       Date:  2007-04

4.  Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trial.

Authors:  Sharon M Kelly; Robert P Schwartz; Kevin E Oʼgrady; Devang Gandhi; Jerome H Jaffe
Journal:  J Addict Med       Date:  2012-06       Impact factor: 3.702

5.  Alcohol use and gender effects on HIV risk behaviors in cocaine-using methadone patients.

Authors:  Carla J Rash; Nancy M Petry
Journal:  Neurobehav HIV Med       Date:  2009-11-01

6.  Preventing HIV in injection drug users: choosing the best mix of interventions for the population.

Authors:  Amy R Wilson; James G Kahn
Journal:  J Urban Health       Date:  2003-09       Impact factor: 3.671

7.  Substance use, childhood sexual abuse, and sexual risk behavior among women in methadone treatment.

Authors:  Lisa R Cohen; Susan Tross; Martina Pavlicova; Mei-Chen Hu; Aimee N Campbell; Edward V Nunes
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

8.  Methadone patients in the therapeutic community: a test of equivalency.

Authors:  James L Sorensen; Siara Andrews; Kevin L Delucchi; Brian Greenberg; Joseph Guydish; Carmen L Masson; Michael Shopshire
Journal:  Drug Alcohol Depend       Date:  2008-11-14       Impact factor: 4.492

9.  The effect of methadone maintenance on positive outcomes for opiate injection drug users.

Authors:  Karen F Corsi; Wayne K Lehman; Robert E Booth
Journal:  J Subst Abuse Treat       Date:  2009-01-15

10.  HIV/hepatitis prevention in drug abuse treatment programs: guidance from research.

Authors:  James L Sorensen; Carmen L Masson; David C Perlman
Journal:  Sci Pract Perspect       Date:  2002-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.